A cohesive continuum of biopharmaceutical manufacturing (clinical & commercial) and development (early & late phase) data has the potential to transform process design, efficiency, and decision making.  The Informatics and Data team in GSK’s Medicinal Science & Technology group is currently developing an end to end CMC domain by using an ecosystem of IT infrastructure and Big Data tools to integrate and curate data from strategic source systems.  Using the team's biopharmaceutical upstream process project as an example, we will discuss how we work, what we have achieved, and where we are going next.  This case study focuses on the approach the team used to integrate biopharmaceutical data and the business value that has been unlocked.  Insights will be shared on team composition, agile project delivery, and how end to end thinking guided our approach.   In addition to project logistics, we will highlight tools and technology that have improved data quality and enabled rapid feedback from subject matter experts. Key deliverables such as data standards, integrated data sets, and analytical use cases will be discussed in the context of work completed on the project.  We will conclude by walking through some of our ambitions in applying machine learning & artificial intelligence techniques as a part of our future direction.<br/>

End to end, data driven approach to unlock new science, improved efficiency, and project acceleration for biopharmaceutical upstream processing

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.